510(k) device
SmartGuard Technology
Medtronic MiniMed · Interoperable Automated Glycemic Controller (QJI, Class II) · First FDA decision Aug 29, 2025, newest Jul 9, 2026Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
510(k) pathway
Device trials
6
Naming "SmartGuard Technology"
MAUDE reports
0
Brand "SmartGuard Technology", since 2015
PubMed studies
10
Mentioning "SmartGuard Technology"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SmartGuard Technology
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
K261962 · Decided Jul 9, 2026 · 28 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
K253701 · Decided Feb 3, 2026 · 71 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
K253585 · Decided Jan 14, 2026 · 58 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "SmartGuard Technology", any status and sponsor, newest update first.
McGill UniversityAcademic, hospital or other
NCT07348432 · 106 participants (planned) · Start Jul 29, 2024 · Primary completion Oct 31, 2026
Device: Automated Insulin Delivery (AID) Systems · For: Insulin Dependent Diabetes Mellitus; Feeding and Eating Disorders; Eating Behavior and 3 more
Sites: Montreal, Canada
Sheba Medical CenterGovernment (non-federal)
NCT06236256 · 42 participants · Start Jan 9, 2024 · Primary completion Aug 20, 2025
Device: MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system · For: Diabetes Mellitus, Type 1
Sites: Ramat Gan, Israel
- The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMsActive, not recruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT04414280 · 1,600 participants (planned) · Start Mar 12, 2020 · Primary completion Apr 2028
Device: Medtronic MiniMed 670G; Medtronic MiniMed 780G and 2 more · For: Diabetes Mellitus, Type 1
Sites: Leuven, Belgium; Aalst, Belgium; Antwerp, Belgium · 38 sites in all
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SmartGuard Technology", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QJI
5,524 reports: 3,680 malfunction, 1,836 injury, 4 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SmartGuard Technology"[tiab]. The summary above synthesizes these.
- Excellent Glycemic Control Maintained by Open-Source Hybrid Closed-Loop AndroidAPS During and After Sustained Physical Activity.
Petruzelkova L, Soupal J, Plasova V, et al. · Diabetes Technol Ther · 2018Evaluation Study, Research Support, Non-U.S. Gov't
- Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study.
Passanisi S, Salzano G, Bombaci B, et al. · Diabetes Care · 2024Multicenter Study
- Effectiveness of SmartGuard Technology in the Prevention of Nocturnal Hypoglycemia After Prolonged Physical Activity.
Petruzelkova L, Pickova K, Sumnik Z, et al. · Diabetes Technol Ther · 2017Comparative Study, Observational Study
- Long-term sensor-augmented pump therapy for neonatal diabetes mellitus: a case series.
Fukuda Y, Ishii A, Kamasaki H, et al. · Clin Pediatr Endocrinol · 2022Case Reports
- Pumps that predict and manage low blood glucose are superior to pumps with stand-alone CGM for reducing hypoglycaemia in type 1 diabetes patients in a real-world setting.
Telliam C, Thivolet C · Diabetes Metab · 2021Research Support, Non-U.S. Gov't
- Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.
De Valk HW, Lablanche S, Bosi E, et al. · Diabetes Technol Ther · 2018Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. · Diabetes Technol Ther · 2019Evaluation Study, Research Support, Non-U.S. Gov't
- Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
Choudhary P, de Portu S, Arrieta A, et al. · Diabet Med · 2019Observational Study, Research Support, Non-U.S. Gov't
- Comparison of flash glucose monitoring with real time continuous glucose monitoring in children and adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion.
Massa GG, Gys I, Bevilacqua E, et al. · Diabetes Res Clin Pract · 2019Clinical Trial, Comparative Study
- "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
Biester T, Kordonouri O, Holder M, et al. · Diabetes Technol Ther · 2017Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QJI.
- SmartAdjust TechnologyInsulet Corporation · 510(k) 2024
- iLet Dosing Decision SoftwareBeta Bionics, Inc. · 510(k) 2026
- Control-IQ+ technologyTandem Diabetes Care, Inc. · 510(k) 2026
- Control-IQ TechnologyTandem Diabetes Care, Inc. · De Novo 2023
- twiist Loop AlgorithmDeka Research and Development Corp. · 510(k) 2026
- iOS CamAPS FXCamDiab · 510(k) 2026
- Omnipod 6 algorithmInsulet Corporation · 510(k) 2026
- DBLG2Diabeloop · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.